Abstract
Mastitis is an infection of the udder caused by bacterial pathogens entering the mammary gland via the teat canal. It is the most prevalent infectious disease in adult dairy cattle. This chapter provides an overview covering the classification of mastitis, anatomy and physiology of the bovine udder, economic impact of mastitis, internal features and histology of the mammary gland, and therapeutic strategies with emphasis on the role of controlled drug release technologies in cattle mastitis prevention and control.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Craven N (1987) Efficacy and financial value of antibiotic treatment of bovine clinical Âmastitis during lactation—a review. Br Vet J 143:410–414
DeGrave FJ, Fetrow J (1993) Economic of mastitis and mastitis control. Vet Clin North Am Food Anim Pract 9:421–517
Gruet P, Maincent P, Berthelot X, Kaltsatos V (2001) Bovine mastitis and intramammary drug delivery: review and perspectives. Adv Drug Deliv Rev 50(3):245–259
Erskine RJ, Kirk JH, Tyler JW, DeGraves FJ (1993) Advances in the therapy for mastitis. Vet Clin North Am Food Anim Pract 9:499–517
Jones TO (1990) Escherichia coli mastitis in dairy cattle—a review of the literature. Vet Bull 60:205–214
Guterbock WM, Eenennaam VAL, Anderson RJ, Gardner IA, Cullor JS, Holmberg CA (1993) Efficacy of intramammary antibiotic therapy for treatment of clinical mastitis caused by environmental pathogens. J Dairy Sci 76:3437–3444
Erskine RJ, Wagner S, DeGraves FJ (2003) Mastitis therapy and pharmacology. Vet Clin North Am Food Anim Pract 19(1):109–138
Huxley JN, Greent MJ, Green LE, Bradley AJ (2002) Evaluation of the efficacy of an internal teat sealer during the dry period. J Dairy Sci 85(3):551–61
Piddock LJV (1996) Does the use of antimicrobial agents in veterinary medicine and animal husbandry select antibiotic-resistant bacteria that infect man and compromise antimicrobial chemotherapy? J Antimicrob Chemother 38(1):1–3
Stelwagen K (2004) What future after antibiotics? Dairy Exporters, p 92
Erskine R, Cullor J, Schaellibaum M, Yancey B, Zecconi A (2004) Bovine mastitis pathogens and trends in resistant to antibacterial drugs. National Mastitis Council, Inc, Verona, Wisconsin, pp 400–414
Berry EA, Hillerton JE (2002) The effect of an intramammary teat seal on new intramammary infections. J Dairy Sci 85:2512–2520
Hillerton JE, Berry EA (2003) The management and treatment of environmental streptococcal mastitis. Vet Clin North Am Food Anim Pract 19(1):157–169
Máire PR, William JM, Ross Paul R, Hill AC (1998) Evaluation of Lacticin 3147 and a teat seal containing this bacteriocin for inhibition of mastitis pathogens. Appl Environ Microbiol 64(6):2287–2290
Meaney WJ (1977) Effect of dry period teat sealant on bovine udder infections. Ir J Agr Res 16:293–299
Twomey DP, Wheelock A, Flynn J, Meaney WJ, Hill C, Ross R (2000) Protection against Staphylococcus aureus mastitis in dairy cows using bismuth based teat seal containing the bacteriocin, lacticin 3147. J Dairy Sci 83:1981–1988
Woolford MW, Williamson JH, Day AM, Copeman PJA (1998) The prophylactic effect of a teat sealer on bovine mastitis during the dry period and the following lactation. N Z Vet J 46:12–19
Meaney WJ, Twomey DP, Flynn J, Hilla C, Ross RP (2001) The use of a bismuth based teat seal and the bacteriocin lacticin 3147 to prevent dry period mastitis in dry cows. In: Council Loahmd (ed) Proceedings of the British Mastitis Conference 2001 Garstang, Lancashire UK. Institute of Animal Health, Newbury UK, pp 24–32
Bismuth subnitrate summary report (1999) In: The European Agency for the evaluation of Medicinal products (EMEA). Committee for veterinary medicinal products
Hemling TM, Henderson KE, Leslie KE, Lim GH, Timms LL (2000) Experimental models for the evaluation of the adherence of dry cow teat sealants. In: Proceedings of 39th Annual Meeting, National Mastitis Council, Atlanta, Georgia, pp 248–249
Carter DH, Luttinger M, Gardner DL (1988) Controlled release parenteral systems for veterinary applications. J Control Release 8(1):15–22
Matschke C, Isele U, van Hoogevest P, Fahr A (2002) Sustained-release injectables formed in situ and their potential use for veterinary products. J Control Release 85(1–3):1–15
Nickerson SC (1992) Anatomy and physiology of the udder. In: Bramley A, Dodd F, Mein G, Bramley J (eds) Machine milking and lactation. Insight Books, Burlington, USA, p 37–68
Preez JHD (1988) Treatment of various forms of bovine mastitis with consideration of udder pathology and the pharmacokinetics of appropriate drugs: a review. J S Afr Vet Assoc 59(3):161–167
Watts JL (1988) Etiological agents of bovine mastitis. Vet Microbiol 16(1):41–66
Bradley AJ (2002) Bovine mastitis: an evolving disease. Vet J 164(2):116–128
Harmon RJ (1996) Controlling contagious mastitis. In: Presented at the 1996 National mastitis council regional meeting Queretero, Mexico. National Mastitis Council Regional Meeting, Queretero, Mexico, p 11
Leigh JA (1999) Streptococcus uberis: a permanent barrier to the control of bovine mastitis? Vet J 157(3):225–238
Calvinho LF, Oliver SP (1998) Characterization of mechanisms involved in uptake of Streptococcus dysgalactiae by bovine mammary epithelial cells. Vet Microbiol 63(2–4): 261–274
McDonald JS (1977) Streptococcal and Staphylococcal mastitis. J Am Vet Med Assoc 170:1157–1159
Harmon RJ (1996) Controlling contagious mastitis. In: Proceedings of the National mastitis council, Madison, WI, pp 11–19
Bradley AJ, Green MJ (2000) A study of the incidence and significance of intramammary enterobacterial infections acquired during the dry period. J Dairy Sci 83(9):1957–1965
Miller G, Dorn CR (1990) Costs of dairy cattle diseases to producers in Ohio. Prev Vet Med 8:171–182
Miller GY, Bartlett PC, Lance SE, Anderson J, Heider LE (1993) Costs of clinical mastitis and mastitis prevention in dairy herds. J Am Vet Med Assoc 202:1230–1236
Schakenraad A, Dijkhuizen A (1990) Economic losses due to bovine mastitis in Dutch dairy herds. J Agr Sci 38:89–92
Bennett RH, Christiansen K, Clifton-Hadley RS (1999) Estimating the costs associated with endemic diseases of dairy cows. J Dairy Res 66:455–459
Ravinderpal G, Wayne HH, El K, Kerry L (1990) Economic of mastitis control. J Dairy Sci 73:3340–3348
Wells SJ, Ott SL, Hillberg Seitzinger A (1998) Key health issues for dairy cattle—new and old symposium: emerging health issues. J Dairy Sci 81:3029–3035
Hibbit KG, Craven N, Batten EH (1992) Anatomy, physiology and immunology of the udder. In: Andrews AH, Blowey RW, Boyd H, Eddy RG (eds) Bovine Medicines: Diseases and Husbandry of Cattle. Blackwell Scientific Publications, Oxford, pp 273–288
Cowie A, Tindal J (1971) The physiology of lactation. Edward Arnold, London, p 1–52
Jack LJW, Capuco A, Wood DL, Aschenbrenner RA, Bitman J, Bright SA (1992) Protein composition of teat canal keratin collected from lactating cows before and after milking. J Dairy Sci 75(suppl 1):195
Mosdoel G (1978) Mastitis pathology in cows, goats and sheep. A literature review (in Norwegian, English summary). Norw Vet Med 30:489–497
Paulrud CO (2005) Basic concepts of the bovine teat canal. Vet Res Commun 29(3):215–245
Sordillo L, Shafer-Weaver K, DeRosa D (1997) Immunobiology of the mammary gland. J Dairy Sci 80:1851–1865
Turner CW (1952) The mammary gland. Lucas Brothers, Columbia, Missouri
Mempham TB (1987) Physiology of Lactation. Open University Press, Philadelphia
Ziv G (1980) Drug selection and use in mastitis: systemic versus local therapy. Vet Med Assoc 176:1109–1115
Craven N (1987) Efficacy and financial value of antibiotic treatment of bovine clinical Âmastitis during lactating—a review. Br Vet J 143:410–422
Sandholm M, Kaartinen L, Pyorala S (1990) Bovine mastitis—why does antibiotic therapy not always work? An overview. J Vet Pharmacol Ther 13(3):248–260
Pyorala S (1988) Indicators of inflammation to evaluate the recovery from acute bovine mastitis. Res Vet Sci 45(2):166–169
Medlicott NJ, Waldron NA, Foster TP (2004) Sustained release veterinary parenteral products. Adv Drug Deliv Rev 56(10):1345–1365
Deicke A, Suverkrup R (1999) Dose uniformity and redispersibility of pharmaceutical suspensions I: quantification and mechanical modelling of human shaking behaviour. Eur J Pharm Biopharm 48(3):225–232
Ziv G, Saran-Rosenzuaig A, Gluckmann E (1973) Kinetic considerations of antibiotic persistence in the udders of dry cows. Zentralblatt Fuer Veterinaermedizin Reihe B 20(6):425–434
Gehring R, Smith GW (2006) An overview of factors affecting the disposition of intramammary preparations used to treat bovine mastitis. J Vet Pharmacol Ther 29(4):237–241
Desmond BJ (1988) Veterinary drug formulations for animal health care: an overview. J Control Release 8(1):5–13
Timms LL, Steffans A, Piggott S, Allen L (1997) Evaluation of a novel persistent barrier teat dip for preventing mastitis during the dry period. In: Proceedings of 36th National Mastitis Council pp 206
Treece JM, Morse GE, Levy C (1960) Lipid analyses of bovine teat canal keratin. J Dairy Sci 49:1240–1244
Comalli M, Eberhart RJ, Griel LC Jr, Rothenbacher H (1984) Changes in the microscopic anatomy of the bovine teat canal during mammary involution. Am J Vet Res 45(11):2236–2242
McNally V, Morgan JP (2002) Inventors: Bimeda Research and Development LTD; Assignee: System for prophylactic treatment of mammary disorders. US Patent 6,340,469, 22 Jan 2002
Williamson JH, Woolford MW, Day AM (1995) The prophylactic effect of a dry cow antibiotic against Streptococcus uberis. N Z Vet J 43:228–234
Notz C (2005) Is Orbeseal® - an internal teat sealant - the answer to mastitis problems in organic dairy herds? In: Workshop PottS, editor. Systems development: quality and safety in organic livestock products Frick, Switerland: Proceedings of the 4th SAFO Workshop. http://orgprints.org/5965/1/5965_OnlinePDF.pdf
Ross J, Switzer RC, Poston MR, Lawhorn GT (1996) Distribution of bismuth in the brain after intraperitoneal dosing of bismuth subnitrate in mice: implications for routes of entry of xenobiotic metals into the brain. Brain Res 725(2):137–154
Slikkerveer A, de Wolff FA (1989) Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp 4:303–323
Corbellini CN, Mauricio B, Monica W, Carlos AI, Pablo J (2002 ) Efficacy of external teat sealant, applied on pre-calving cows in grazing system. In: National Mastitis Council Annual Meeting Proceedings, NMC, USA. //www.westagro.com/NMC_Presentation_Janowicz_OnlinePDF.pdf.
Hemling T, Henderson M, Leslie K, Lim G, Timms L (2000) Experimental models for the evaluation of the adherence of dry cow teat sealants. In: NMC annual meeting proceedings, NMC, USA, pp 248–249
Querengasser J, Geishauser T, Querengasser K, Bruckmaier R, Fehlings K (2002) Comparative evaluation of SIMPL silicone implants and NIT natural teat inserts to keep the teat canal patent after surgery. J Dairy Sci 85(7):1732–1737
Huston GE, HC W (1983) Effect of the intramammary device on milk infection status, yield, and somatic cell count and on the morphological features of the lactiferous sinus of the bovine udder. Am J Vet Res 44(10):1856–1860
Nickerson SC, Boddie RL, Owens WE, Watts JL (1990) Effects of novel intramammary device models on incidence of mastitis after experimental challenge. J Dairy Sci 73(10):2774–2784
Klink PR, Ferguson TH (1998) Formulation of veterinary dosage forms. In: Hardee GE, Baggot JD (eds) Development and formulation of veterinary dosage forms, 2nd edn. Marcel Dekker. Inc, New York, pp 145–229
Cherng-Ju K (2000) Controlled release dosage form design. CRC Press, Boca Raton, FL
Ding X, Alani, Adam, WG, Robinson, Joseph, R (2005) Extended-release and targeted drug delivery systems. Remington: the science and practice of pharmacy, 21 ed. Lippincott Williams and Wilkins: Baltimore, MD, pp 939–964. Available from http://books.google.co.uk/books?id=NFGSSSbaWjwC&printsec=frontcover#v=onepage&q&f=false
Brannon-Peppas L (1997) Polymers in controlled drug delivery. In: Medical Plastic and Biomaterials Magazine. http://www.mddionline.com/article/polymers-controlled-drug-delivery
Rathbone MJ, Ogle CR (2000) Mechanism of drug release from veterinary drug delivery systems. In: Rathbone MJ, Gurney R (eds) Controlled release veterinary drug delivery. Elsevier Science, Amsterdam, pp 17–50
Ron E, Langer R (1992) Erodible systems. In: Kydonieus A (ed) Treatise on controlled drug delivery. Marcel Dekker, New York, pp 199–224
Gopferich A, Tessmar J (2002) Polyanhydride degradation and erosion. Adv Drug Deliv Rev 54(7):911–931
Rosen HB, Chang J, Wnek GE, Linhardt RJ, Langer R (1983) Bioerodible polyanhydrides for controlled drug delivery. Biomaterials 4(2):131–133
Shah SS, Kulkarni MG, Mashelkar RA (1991) Swellable hydrogel matrices for the release of the pendent chain-linked active ingredients over extended time periods. J Appl Polym Sci 43(10):1879–1884
Jantzen GM, Robinson JR (1995) Christopher T. In: Banker GSR (ed) Modern pharmaceutics, 3rd edn. Marcel Dekker Inc, New York, pp 575–609
Aarestrup FM, Larsen HD, Jensen NE (1999) Characterization of Staphylococcus simulans strains isolated from cases of bovine mastitis. Vet Microbiol 66(2):165–170
Colombo P, Santi P, Bettini R, Peppas NA CSB (2000) Drug release from swelling-controlled system. In: Wise D (ed) Hand Book of Pharmaceutical Controlled Release Technology. Marcel Dekker, Inc., New York, pp 183–209
Kim SW, Bae YH, Okano T (1992) Hydrogels: swelling, drug loading and release. Pharm Res 9(3):283–290
Bettini R, Colombo P, Massimo G, Catellani P, Vitali T (1994) Swelling and drug release in hydrogel matrices: polymer viscosity and matrix porosity effects. Eur J Pharm Sci 2:213–219
Nam KW, Watanabe J, Ishihara K (2002) pH-modulated release of insulin entrapped in a spontaneously formed hydrogel system composed of two water-soluble phospholipid polymers. J Biomater Sci Polym Ed 13(11):1259–1269
Namkung S, Chu C (2006) Effect of solvent mixture on the properties of temperature- and pH-sensitive polysaccharide-based hydrogels. J Biomater Sci Polym Ed 17(5):519–546
Pei Y, Chen J, Yang L, Shi L, Tao Q, Hui B (2004) The effect of pH on the LCST of poly(N-isopropylacrylamide) and poly(N-isopropylacrylamide- co-acrylic acid. J Biomater Sci Polym Ed 15(5):585–594
Qiu Y, Park K (2001) Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 53(3):321–339
Saslawski O, Weingarten C, Benoit JP, Couvreur P (1988) Magnetically responsive microspheres for the pulsed delivery of insulin. Life Sci 42(16):1521–1528
Lavon I, Kost J (1998) Mass transport enhancement by ultrasound in non-degradable polymeric controlled release systems. J Control Release 54(1):1–7
Graham NB, McNeill ME (1984) Hydrogels for drug delivery. Biomaterials 5:27–36
Jain RA, Rhodes CT, Railkar AM, Malick AW, Shah NH (2000) Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables. Eur J Pharm Biopharm 50(2):257–62
Hatefi A, Amsden B (2002) Biodegradable injectable in situ forming drug delivery systems. J Control Release 80(1–3):9–28
Haglund BO, Joshi R, Himmelstein KJ (1996) An in situ gelling system for parenteral delivery. J Control Release 41(3):229–235
Ruel-Gariepy E, Leroux J-C (2004) In situ-forming hydrogels—review of temperature-Âsensitive systems. Eur J Pharm Biopharm 58(2):409–426
Tipton AJ, Dunn RL (2000) In-situ gelling systems. In: Senior JH, Radomsky M (eds) Sustained Release Injectable Products. Interpharm Press, Denver, CO, pp 71–102
Dunn R, English J, Cowsar DA, Vanderbilt DV (1990) Inventors: Atrix laboratories; Assignee: Biodegradable in-situ forming implants and methods of producing the same. US Patent 4,938,763
Rathi RC, Zentner, GM, Jeong, B (2001) Inventor: MacroMed, Inc. (Sandy, UT), USA; Assignee: Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US Patent 6,201,072
Jeong B, Bae YH, Kim SW (2000) Drug release from biodegradable injectable thermosensitive hydrogel of PEG-PLGA-PEG triblock copolymers. J Control Release 63(1–2):155–163
Amiji MM, Lai PK, Shenoy DB, Rao M (2002) Intratumoral administration of paclitaxel in an in situ gelling poloxamer 407 formulation. Pharm Dev Technol 7(2):195–202
Gutowska A, Jeong B, Jasionowski M (2001) Injectable gels for tissue engineering. Anat Rec 263(4):342–349
Ismail FA, Napaporn J, Hughes JA, Brazeau GA (2000) In situ gel formulations for gene delivery: release and myotoxicity studies. Pharm Dev Technol 5(3):391–397
Lin H-R, Sung KC (2000) Carbopol/pluronic phase change solutions for ophthalmic drug delivery. J Control Release 69(3):379–388
Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D (2001) In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 229(1–2):29–36
Rozier A, Mazuel C, Grove J, Plazonnet B (1989) Gelrite(R): a novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm 57(2):163–168
Kubo W, Miyazaki S, Attwood D (2003) Oral sustained delivery of paracetamol from in situ-gelling gellan and sodium alginate formulations. Int J Pharm 258(1–2):55–64
Kubo W, Miyazaki S, Dairaku M, Togashi M, Mikami R, Attwood D (2004) Oral sustained delivery of ambroxol from in situ-gelling pectin formulations. Int J Pharm 271(1–2):233–240
Miyazaki S, Kubo W, Attwood D (2000) Oral sustained delivery of theophylline using in-situ gelation of sodium alginate. J Control Release 67(2–3):275–280
Miyazaki S, Aoyama H, Kawasaki N, Kubo W, Attwood D (1999) In situ-gelling gellan formulations as vehicles for oral drug delivery. J Control Release 60(2–3):287–295
Miyazaki S, Kawasaki N, Kubo W, Endo K, Attwood D (2001) Comparison of in situ gelling formulations for the oral delivery of cimetidine. Int J Pharm 220(1–2):161–168
Miyazaki S, Kawasaki N, Endo K, Attwood D (2001) Oral sustained delivery of theophylline from thermally reversible xyloglucan gels in rabbits. J Pharm Pharmacol 53(9):1185–1191
Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD (2000) Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 21(21):2155–2161
Ruel-Gariepy E, Leclair G, Hildgen P, Gupta A, Leroux J-C (2002) Thermosensitive chitosan-based hydrogel containing liposomes for the delivery of hydrophilic molecules. J Control Release 82(2–3):373–383
Cohen S, Lobel E, Trevgoda A, Peled Y (1997) A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release 44(2–3):201–208
Takahashi A, Suzuki S, Kawasaki N, Kubo W, Miyazaki S, Loebenberg R (2002) Percutaneous absorption of non-steroidal anti-inflammatory drugs from in situ gelling xyloglucan formulations in rats. Int J Pharm 246(1–2):179–186
Lindell K, Engstrom S (1993) In vitro release of timolol maleate from an in situ gelling polymer system. Int J Pharm 95(1–3):219–228
Srividya B, Cardoza RM, Amin PD (2001) Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. J Control Release 73(2–3):205–211
Liu Z, Li J, Nie S, Liu H, Ding P, Pan W (2006) Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 315(1–2):12–17
Fawaz F, Koffi A, Guyot M, Millet P (2004) Comparative in vitro-in vivo study of two quinine rectal gel formulations. Int J Pharm 280(1–2):151–162
Johnston TP, Punjabi MA, Froelich CJ (1992) Sustained delivery of Interleukin-2 from a Poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res 9(3):425–434
Edsman K, Carlfors J, Petersson R (1998) Rheological evaluation of poloxamer as an in situ gel for ophthalmic use. Eur J Pharm Sci 6(2):105–112
Veyries ML, Couarraze G, Geiger S, Agnely F, Massias L, Kunzli B (1999) Controlled release of vancomycin from Poloxamer 407 gels. Int J Pharm 192(2):183–193
Paavola A, Yliruusi J, Kajimoto Y, Kalso E, Wahlström T, Rosenberg P (1995) Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block. Pharm Res 12(12):1997–2002
DesNoyer JR, McHugh AJ (2003) The effect of Pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release 86(1):15–24
De la Torre PM, Torrado S, Torrado S (2003) Interpolymer complexes of poly(acrylic acid) and chitosan: influence of the ionic hydrogel-forming medium. Biomaterials 24(8): 1459–1468
Torrado S, Prada P, de la Torre PM, Torrado S (2004) Chitosan-poly(acrylic) acid polyionic complex: in vivo study to demonstrate prolonged gastric retention. Biomaterials 25(5): 917–923
Norling T, Lading P, Engstrom S, Larsson K, Krog N, Nissen SS (1992) Formulation of a drug delivery system based on a mixture of monoglycerides and tryglycerides for use in the treatment of periodontal disease. J Clin Periodontol 19:687–692
Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, Sane S (2002) Sustained delivery of human growth hormone from a novel gel system: SABERTM. Biomaterials 23(22):4353–4358
Preul MC, Bichard WD, Muench TR (2003) Toward optimal tissue sealants for neurosurgery: use of a novel hydrogel sealant in a canine durotomy repair model. Neurosurgery 53(5): 1189–1199
Waring MJ, Parsons D (2001) Physico-chemical characterisation of carboxymethylated spun cellulose fibres. Biomaterials 22(9):903–912
Walker M, Hobot JA, Newman GR, Bowler PG (2003) Scanning electron microscopic examination of bacterial immobilisation in a carboxymethyl cellulose (AQUACEL(R)) and alginate dressings. Biomaterials 24(5):883–890
Scherr GH Inventor; Scherr GH (1998) Assignee. Alginate foam product for wound dressing. US Patent 5,718,916. 19970203
Matthew IR, Browne RM, Frame JW, Millar BG (1995) Subperiosteal behaviour of alginate and cellulose wound dressing materials. Biomaterials 16(4):275–278
Suzuki Y, Nishimura Y, Tanihara M, Suzuki K, Nakamura T, Shimizu Y, Yamawaki Y, Kakimaru Y (1998) Evaluation of a novel alginate gel dressing: cytotoxicity to fibroblasts in vitro and foreign-body reaction in pig skin in vivo. J Biomed Mater Res 39(2):317–322
Bowler PG, Jones SA, Davies BJ, Coyle E (1999) Infection control properties of some wound dressings. J Wound Care 8(10):499–502
Malmsten M, Lindman B (1992) Self-assembly in aqueous block co-polymer solution. Micromolecules 25:5446–5450
Katakam M, Ravis WR, Banga AK (1997) Controlled release of human growth hormone in rats following parenteral administration of poloxamer gels. J Control Release 49(1):21–26
Jeong B, Choi YK, Bae YH, Zentner G, Kim SW (1999) New biodegradable polymers for injectable drug delivery systems. J Control Release 62(1–2):109–114
Jeong B, Bae YH, Kim SW (2000) In situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof. J Biomed Mater Res 50(2):171–177
Joshi R, Robinson DH, Himmelstein KJ (1999) In vitro properties of an in situ forming gel for the parenteral delivery of macromolecular drugs. Pharm Dev Technol 4(4):515–522
Paulsson M, Hagerstrom H, Edsman K (1999) Rheological studies of the gelation of deacetylated gellan gum (Gelrite(R)) in physiological conditions. Eur J Pharm Sci 9(1):99–105
Tipton AJ (1999) Inventor: Southern BioSystems, Inc. (Birmingham, AL); Assignee: High viscosity liquid controlled delivery system as a device. USA
Burns PJ, Gibson JW, Tipton AJ (1997) Inventors: Southern BioSystems, Inc. (Birmingham, AL); Assignee: Compositions suitable for controlled release of the hormone GnRH and its analogs. USA
Dunn R (2005) Application of the ATRIGEL® implant drug delivery technology for patient-friendly, cost-effective product development. Drug Deliv Technol 5(10)
Polson AM, Dunn RL, Fulfs JC, Godoski JC, Polson AP, Southard GL, Yewey GL (1993) Periodontal pocket treatment with subgingival doxycycline from a biodegradable system. J Dent Res 72:360
Rathi RC, Zentner GM, Jeong B (2000) Inventors: MacroMed, Inc. (Sandy, UT),USA; Assignee: Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reversal thermal gelation properties. US Patent, 6,117949
Zentner GM, Rathi R, Shih C, McRea JC, Seo M-H, Oh H (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72(1–3): 203–215
Matthes K, Enqiang L, Brugge WR (2005) Feasibility of endoscopic ultrasound-guided oncogel (ReGel/Paclitaxel) injection into the pancreas of the pig: preliminary results. Gastrointest Endosc 61(5):AB292
Dunn R, English J, Vanderbilt A (1995) Inventors: Atrix Laboratory, Inc.; Assignee: Biodegradable in-situ forming implants and methods of producing the same. United States
Dunn R, English J, Cowsar D, Vanderblit DV (1998) Inventors: Atrix Laboratories, Incorporated; Assignee: Biodegradable in-situ forming implants and methods of producing the same. US Patent 5733950
Chogle S, Mickel AK (2003) An in vitro evaluation of the antibacterial properties of barriers used in guided tissue regeneration. J Endod 29(1):1–3
Polson AM, Dunn RL, Polson AP (1993) Healing patterns associated with an ATRISORB barrier in guided tissue regenerartion. Compendium 14:1162–1172
FowlerJr JE, Flanagan M, Gleason DM, Klimberg IW, Gottesman JE, Sharifi R (2000) Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer. Urology 55(5):639–642
Ravivarapu HB, Moyer KL, Dunn RL (2000) Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide. Int J Pharm 194(2):181–191
Gibson JW, Sullivan SA, Middleton JC, Tipton AJ (2002) Inventors: Southern Biosystems, Inc. (Birmingham, AL); Assignee: High viscosity liquid controlled delivery system and medical or surgical device. USA
Hoemann CD, Hurtig M, Rossomacha E, Sun J, Chevrier A, Shive MS (2005) Chitosan-glycerol phosphate/blood implants improve hyaline cartilage repair in ovine microfracture defects. J Bone Joint Surg Am 87(12):2671–2686
Shedden AH, Laurence J, Barrish A, Olah TV (2001) Plasma timolol concentrations of timolol maleate: timolol gel-forming solution (TIMOPTIC-XE) once daily versus timolol maleate ophthalmic solution twice daily. Doc Ophthalmol 103(1):73–79
Polson A, Southard GL, Dunn RL, Polson AP, Yewey GL, Swanbom DD, Fulfs JC, Rodgers PW (1995) Periodontal healing after guided tissue regeneration with Atrisorb barriers in beagle dogs. Int J Periodontics Restorative Dent 15(6):574–589
Zhang L, Parsons DL, Navarre C, Kompella UB (2002) Development and in-vitro evaluation of sustained release Poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 85(1–3):73–81
Sullivan SA, Gibson JW, Burns PJ, Squires EL, Thompson DL, Tipton AJ (1998) Sustained release of progesteron and estradiol from the SABERTM delivery system: in vitro and in vivo release rates. In: Proceedings of the International Symposium on Controlled Release Bioactive Material, Controlled Release Society, Inc, Boston MA, pp 653–654
Fleury J, Squires EL, Betschart R, Gibson J, Sullivan S, Tipton A (1998) Evaluation of the SABERTM delivery system for the controlled release of deslorelin for advancing ovulation in the mare: effect of formulation and dose. Proceedings of the International Symposium on Controlled Release Bioactive Material, Controlled Release Society, Inc, Boston MA, pp 657–658
Betschart R, Fleury J, Squires EL, Nett T, Gibson J, Sullivan S (1998) Evaluation of the SABERTM delivery system for the controlled release of the GnRH analogue deslorelin for advancing ovulation in Mares: effect of gamma radiation. Proceedings of the International Symposium on Controlled Release Bioactive Material, Controlled Release Society, Inc, Boston MA655–656
Barb R, Kraeling RG, Thompson DJ, Gibson J, Sullivan S, Simon B (1999) Evaluation of the saber delivery system for the controlled release of Deslorelin: effect of dose in estrogen primed ovarectomized gilts. Proceedings of the International Symposium on Controlled Release Bioactive Material, Controlled Release Society, Inc, Boston MA, pp 1170–1171
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Controlled Release Society
About this chapter
Cite this chapter
Alany, R.G., Bhattarai, S., Pranatharthiharan, S., Devarajan, P.V. (2013). Intramammary Delivery Technologies for Cattle Mastitis Treatment. In: Rathbone, M., McDowell, A. (eds) Long Acting Animal Health Drug Products. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4439-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4439-8_13
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4438-1
Online ISBN: 978-1-4614-4439-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)